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ABSTRACT 
Aging and the menopause transition are both intricately linked to cognitive changes 
during mid-life and beyond. Clinical literature suggests the age at menopause onset can 
differentially impact cognitive status later in life. Yet, little is known about the 
relationship between behavioral and brain changes that occur during the transitional stage 
into the post-menopausal state. Much of the pre-clinical work evaluating an animal model 
of menopause involves ovariectomy in rodents; however, ovariectomy results in an 
abrupt loss of circulating hormones and ovarian tissue, limiting the ability to evaluate 
gradual follicular depletion. The 4-vinylcyclohexene diepoxide (VCD) model simulates 
transitional menopause in rodents by selectively depleting the immature ovarian follicle 
reserve and allowing animals to retain their follicle-deplete ovarian tissue, resulting in a 
profile similar to the majority of menopausal women. Here, Vehicle or VCD treatment 
was administered to ovary-intact adult and middle-aged Fischer-344 rats to assess the 
cognitive effects of transitional menopause via VCD-induced follicular depletion over 
time, as well as to understand potential interactions with age, with VCD treatment 
beginning at either six or twelve months of age. Results indicated that subjects that 
experience menopause onset at a younger age had impaired spatial working memory 
early in the transition to a follicle-deplete state. Moreover, in the mid- and post- 
menopause time points, VCD-induced follicular depletion amplified an age effect, 
whereby Middle-Aged VCD-treated animals had poorer spatial working and reference 
memory performance than Young VCD-treated animals. Correlations suggested that in 
middle age, animals with higher circulating estrogen levels tended to perform better on 
spatial memory tasks. Overall, these findings suggest that the age at menopause onset is a 
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critical parameter to consider when evaluating learning and memory across the transition 
to reproductive senescence. From a translational perspective, this study informs the field 
with respect to how the age at menopause onset might impact cognition in menopausal 
women, as well as provides insight into time points to explore for the window of 
opportunity for hormone therapy during the menopause transition to attenuate age- and 
menopause- related cognitive decline, and produce healthy brain aging profiles in women 
who retain their ovaries throughout the lifespan.   
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Cognitive Changes Across the Menopause Transition: A Longitudinal Evaluation of the 
Impact of Age and Ovarian Status on Spatial Memory 
Introduction 
Women typically experience a natural transition to menopause, or the complete 
cessation of menses resulting from follicular depletion of the ovaries, beginning around 
the fifth decade of life. While menopause marks the end of the reproductive life stage, 
natural menopause is not a sudden life event. Rather, in women, it is a transitional period 
into a reproductively senescent state that typically lasts between four and eight years 
(NAMS, 2015). A hallmark of the natural transition to menopause is a gradual—but 
ultimately significant—drop in endogenously circulating gonadal hormone levels 
(Timiras et al., 1995). The menopause transition, often referred to in the clinic as 
“perimenopause” or “climacteric” (Soules et al., 2001), is a normal transitional stage of 
irregular menstrual cycles and erratic, fluctuating ovarian hormone levels that are often 
accompanied by a range of physiological indicators including vasomotor symptoms (e.g. 
hot flashes, night sweats), dyspareunia, vaginal dryness and atrophy, sleep and mood 
disturbances, and memory complaints (Al-Safi & Santoro, 2014; Weber et al., 2013). In 
2001, the Stages of Reproductive Aging Workshop (STRAW) proposed a standardized 
staging system for reproductive aging during the natural menopause transition. The 
STRAW staging system was recently updated in 2012 to encompass the most up-to-date 
research in the field and a more diverse range in the population of women since the 
original model was implemented (Harlow et al., 2012). Stages range from -5 to +2, and 
criteria for each stage includes typical stage length, menstrual cycle activity, ovarian 
biomarkers (e.g. endocrine status, antral follicle count) and common symptomology 
    2 
during the transition: -5 to -3 signify reproductive years, -2 to -1 are considered the 
menopausal transition, 0 signifies the final menstrual period, and +1 and +2 are the early 
and late post-menopausal life stages, respectively (Harlow et al., 2012; Soules et al., 
2001). Clinically, the transitional stage is defined as extending through the menopause 
(i.e. the final menstrual period), and menopause is then retrospectively confirmed after 
one year of a complete cessation of menses (NAMS, 2015; Hoffman et al., 2012). Of 
note, this transitional stage only occurs with natural menopause; surgical menopause via 
oophorectomy (surgical removal of the ovaries) with or without hysterectomy (surgical 
removal of the uterus) occurring prior to the menopause transition results in an abrupt, 
rather than gradual, loss of gonadal hormone production (NAMS, 2015). Transitional 
versus surgical menopause can result in different hormone profiles that may impact the 
trajectory of aging in the post-menopausal life stage.  
Normal aging and reproductive senescence have each been associated with 
memory impairments (Tulving & Craik, 2000; Sullivan & Fugate Woods, 2001). 
Whether a woman experiences transitional or surgical menopause, and the age at which 
she experiences it, may impact cognitive performance later in life. Of note, research has 
shown that women who undergo oophorectomy before the onset of natural menopause 
tend to have more severe memory impairments and an increased risk of Alzheimer’s 
disease than women who retain their ovaries throughout the menopause transition, or 
have an oophorectomy after the transition to menopause is complete. That is, women who 
were oophorectomized later in life (i.e. post-menopause) achieved higher short-term 
verbal memory scores than women who had surgery at a younger age. In addition, the 
number of years since surgical menopause had a strong negative impact on performance 
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on the short-term verbal memory task, such that a longer period of time since surgical 
menopause was related to poorer verbal memory performance, regardless of age at the 
time of the study (Nappi et al., 1999; Rocca et al., 2007, 2012). While menopause 
typically occurs around age 51 (NAMS, 2015), some women experience early-onset 
menopause, defined as the final menstrual period occurring before the age of 45, or 
premature ovarian failure, defined as the final menstrual period occurring before age 40 
(Shuster et al., 2010). Spontaneous premature ovarian failure affects an estimated 1% of 
women and is not yet well understood, although it may have unique genetic and immune 
factors associated with its onset (Pal & Santoro, 2002; Shuster et al., 2010; Simpson and 
Rajkovic, 1999). Indeed, elucidating the effects of premature, early, and typical 
menopause time points may provide insight into the divergent effects observed for 
memory and other age-related health consequences seen later in life.  
In the United States, human life expectancy is increasing, particularly for women 
(Xu et al., 2012; Singh et al., 1996); in 1990, the average female life expectancy at birth 
was 78.84, and the 2013 estimate was 81.42 years (Murray et al., 2015). Yet, the median 
age of spontaneous menopause onset —about age 51— has remained relatively stable 
across time (Amundsen & Diers, 1970, 1973). Indeed, the average expected lifespan is 
increasing worldwide (Murray et al., 2015). Given that the world estimate of average life 
expectancy for women is 70 years (The World Factbook 2014 estimate), this suggests 
that many women worldwide are now spending a significant proportion of their lives in a 
hypoestrogenic state (Mennenga & Bimonte-Nelson, 2013; Sherwin, 2003). In the United 
States alone, approximately 14.88% of the population is over the age of 65 (The World 
Factbook 2015 estimate). As the “baby boomer” generation ages, this percentage is 
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expected to increase to 20% by the year 2020 (U.S. Census Bureau 2007, 2010). It is now 
more important than ever to understand the impact that natural and surgical ovarian 
hormone loss has on memory decline with age, and to discover potential hormone therapy 
options to maintain a high quality of life for women throughout the entire lifespan, 
including the post-reproductive life stage. 
In the basic science laboratory, the gold standard for evaluating the impact of 
gonadal hormone loss and exogenous administration of hormone therapy on memory 
performance in an animal model is ovariectomy (Ovx), or the surgical removal of the 
ovaries. However, this classic technique only models approximately 13% of women who 
undergo surgical menopause via bilateral oophorectomy (CDC, 2010; Hall et al., 2010). 
The vast majorities of women experience a gradual menopause transition and typically 
maintain their reproductive organs into the post-menopausal life stage. While the Ovx 
model provides an excellent “blank hormonal slate” from which researchers can 
systematically control hormone exposures and evaluate the unique impacts of each 
hormone administered, it is noteworthy that in humans and other mammals, the post-
menopausal ovary continues to secrete low amounts of endogenous sex hormones, 
including androgens (Mayer et al., 2004; Timiras et al., 1995). Therefore, the Ovx model, 
while extremely useful in many experimental designs, does not provide an illustrative 
representation of the endogenous hormonal milieu of most menopausal women. 
Moreover, rats and mice, the animal models most-often utilized in hormone research, do 
not experience menopause; they undergo estropause (Finch, 2014; Meites & Lu, 1994). 
In contrast to human menopause, whereby immature follicles in the ovaries are depleted 
via natural atresia, rodents do not experience follicular loss to the same extent as women. 
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Rather, the driving mechanism underlying reproductive senescence in rodents is a 
significant dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis in middle age 
(Finch, 2014). This results in a persistent estrus, repetitive pseudopregnancy, or persistent 
diestrus state in which the rat or mouse stops cycling normally (Finch, 2014; Meites & 
Lu, 1994; Lu et al., 1979; Westwood, 2008). Briefly, the hallmark of persistent estrus 
involves low to moderate levels of estrogens and androgens, and low levels of 
progestogens. The pseudopregnancy hormone profile consists of higher levels of 
progestogens from post-ovulatory corpora lutea that are maintained for an extended 
period of time, and similar levels of estrogens to the persistent estrus state. Finally, the 
persistent diestrous (or anestrous) state is marked by low levels of all circulating gonadal 
steroids and a lack of corpora lutea in the ovary (Lu et al., 1979). Overall, these changes 
in the rodent estrous cycle mark the onset of reproductive senescence. Although Ovx and 
intact aging models are informative for understanding hypothalamic-pituitary-gonadal 
interactions during the aging, each of these models is limited as a suitable model for the 
unique follicular and hormone changes that occur during the human menopause 
transition. 
In the early 2000’s, Dr. Loretta Mayer and colleagues introduced a rodent model 
of transitional menopause using 4-vinylcyclohexene diepoxide (VCD). VCD is a 
metabolite of 4-vinylcyclohexene, a chemical formed from the dimerization of the 
industrial chemical butadiene (a suspected teratogen [Melnick & Kohn, 1995]) that is 
utilized in the manufacturing of a variety of products, including plasticizers, synthetic 
rubber, insecticides, flame-retardants and antioxidants (Hoyer et al., 2001). VCD 
selectively targets primordial and primary ovarian follicles via atresia, or programmed 
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cell death, in the ovary (Hoyer et al., 2001; Springer et al., 1996c), resulting in 
accelerated follicular depletion and eventual ovarian failure in rodents (Borman et al., 
1999; Flaws et al., 1994; Hirshfield, 1991; Hoyer et al., 2001; Hu et al., 2001a, 2001b; 
Kao et al., 1999; Mayer et al., 2002, 2004, 2005; Springer et al., 1996a, 1996b, 1996c). 
Because female mammals are generally considered to be born with all of the oocytes they 
will ever have, ovarian follicle reserve count is an important biomarker for reproductive 
capacity. Indeed, antral follicle count (quantified via transvaginal ultrasound) and 
antimüllerian hormone levels are considered to be some of the best clinical markers to 
date to measure ovarian reserve of non-growing or resting follicles, and therefore 
reproductive capacity, in women (Hansen et al., 2011; Hansen, 2013). The VCD model’s 
ability to specifically target the non-growing follicle reserve in rodents to accelerate 
apoptotic processes in immature ovarian follicles provides us with an excellent 
translational tool for evaluating ovarian and hormone changes that occur across the 
transition into a follicle-deplete state. Indeed, VCD-treated animals have been shown to 
have hormone profiles similar to transitionally menopausal women (Timiras et al., 1995; 
Frye et al., 2012) while retaining follicle-deplete ovarian tissue as do most women.  
Previous findings from our laboratory suggest that the impact of hormone loss on spatial 
memory performance in the rat differs depending on a surgical or transitional menopause 
state, as induced by VCD treatment (Acosta et al., 2009). The VCD-induced menopause 
model is ideal for studying aging and the menopause transition, including the early stages 
of the transition, as this is analogous to the time point when a multitude of physiological 
and affective symptoms of menopause begin to present in many women (Hale et al., 
2014).  
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Here, the goal was to elucidate the effects of transitional menopause via VCD-
induced follicular depletion on spatial memory in ovary-intact Fischer-344 rats, as well as 
to understand potential interactions of follicular depletion with age, with VCD treatment 
beginning at either six or twelve months of age. The goals were threefold: (1) to 
investigate the two age groups’ learning and memory capacity across mid-life aging with 
and without transitional menopause, (2) to evaluate the hormonal and ovarian changes 
that occur during follicular depletion in rodents that may relate to behavioral changes, 
and, (3) to understand potential interactions among age, menopause onset, and cognitive 
changes. Of note, other laboratories have conducted cross-sectional studies looking at 
age-related memory decline in males (Bizon et al., 2009; Frick et al., 1995; Markowska, 
1999b) and females (Markowska, 1999a, Markowska and Breckler, 1999). However, 
testing naïve animals at different ages does not allow us to compare individual 
performance over time as aging ensues. Markowska and Savonenko conducted a 
longitudinal study assessing the effect of practice on cognition during aging in male rats, 
and found that even one previous experience benefited repeated testing later in life for 
working and reference memory tasks (2002a). Additionally, Ovx and sham female 
Fischer-344 rats have been longitudinally evaluated for cognitive performance over a 
nine-month period, beginning in middle-age (Markowska & Savovnenko, 2002b). Our 
laboratory recently demonstrated that cognitive practice can attenuate age-related decline 
in males and females by enhancing performance on the practiced task when tested at a 
later age compared to naïve, age-matched animals; additionally, cognitive practice 
confers a sex-specific benefit for females to transfer enhanced performance capacity to a 
novel cognitive task (Talboom et al., 2014). Evaluating spatial working and reference 
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memory performance in the same animals over time would allow us to evaluate memory 
changes and/or maintenance within subjects across the transition to a follicle-deplete 
state. Subjects were trained, beginning at six or twelve months of age, on a water radial-
arm maze task, administered VCD treatment, and then repeatedly tested on the same task 
over a four-month period during the VCD-induced menopausal transition to examine the 
impact that erratic hormone profiles often seen during the menopause transition have on 
memory, how memory for a familiar task varies across this transition, and whether the 
age at follicular-depletion initiation matters for cognitive performance.  
Methods 
Subjects 
Subjects were 56 female virgin Fischer-344 rats obtained from the National 
Institute on Aging colony at Harlan Laboratories (Indianapolis, IN). At the beginning of 
the study, rats were either 6 months (n=28) or 12 months (n=28) of age. Upon arrival, rats 
were pair-housed, given food and water ad libitum, and maintained on a 12-hour 
light/dark cycle for the entirety of the study. Animals were given one week to acclimate 
in the vivarium prior to the commencement of the experiment. All procedures were 
approved by the Arizona State University Institutional Animal Care and Use Committee 
and adhered to National Institutes of Health standards. 
Experimental Design 
 An overview of the study timeline can be found in Figure 1. 
Water radial-arm maze training. One week after arrival, subjects were trained 
for 12 days on the win-shift water radial-arm maze (WRAM), evaluating spatial working 
and reference memory, as previously described (Figure 2a; Bimonte & Denenberg, 1999; 
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Bimonte et al., 2000, 2002, 2003; Bimonte-Nelson et al., 2003, 2004). Briefly, the 
WRAM is an eight-arm apparatus (each arm 38.1 x 12.7 cm) filled with room 
temperature water (18-20°C) tinted with non-toxic, powdered black tempera paint. Four 
out of eight arms contained a hidden platform (11 cm diameter) just beneath the surface 
of the water. Each subject was assigned to a set of unique platform locations that 
remained fixed across all days of testing, including the training period and all subsequent 
retests. The room contained salient extra-maze spatial cues to aid in spatial navigation.  
All subjects received a total of four trials per day of testing. Each rat was released from 
the start arm and had three minutes to find a hidden platform. If the platform was not 
located within the allotted three-minute trial, the experimenter led the animal to the 
nearest platform. Once the platform was located, the rat remained on the platform for 15 
seconds before the experimenter returned the animal to its heated testing cage for an 
inter-trial interval (ITI) of 30 seconds. During the ITI, the just-found platform was 
removed from the maze, and the experimenter cleaned the water to remove any debris 
and to disturb potential olfactory cues. The rat was placed back into the start arm and 
given three minutes to locate the next platform. Because one platform was removed after 
each trial, the working memory system was increasingly taxed as trials progressed. The 
daily testing session ended when the animal had located all four hidden platforms.  
Water radial-arm maze working and reference memory error types were 
quantified as previously described (Bimonte et al., 2000, 2002; Hyde et al., 2000; Braden 
et al., 2010, 2011). Briefly, a working memory correct error (WMC) was defined as an 
entry into an arm that previously contained a platform within a day. Reference memory 
errors (RM) were the first entries (within a day) into any arm that never contains a 
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platform. Working memory incorrect errors (WMI) were considered to be all subsequent 
entries (within a day) into arms that never contained a platform. An arm entry was 
counted when the tip of the rat’s snout crossed a mark delineated on the outside of the 
arm (not visible from inside the maze; 11 cm into the arm). Total errors for each trial 
were calculated by summing WMC, RM, and WMI errors made per trial. 
Injections. Animals in each age cohort were randomly assigned to either the 
Vehicle or VCD condition. Treatment groups were classified as either “Young Vehicle” 
(n=13), “Young VCD” (n=15), “Middle-Aged Vehicle” (n=13), or “Middle-Aged VCD” 
(n=15) to signify whether subjects were young (6 mo) or middle-aged (12 mo) at the 
beginning of the experiment. VCD was administered for a total of 15 injection days via 
intraperitoneal injection at 160 mg/kg/day (SenesTech Inc., Flagstaff, AZ) in 50% 
dimethyl sulfoxide (DMSO)/saline vehicle (Sigma-Aldrich, St. Louis, MO). The vehicle 
injection was 0.5 ml of 50% DMSO/saline solution. Daily VCD injection volume was 
determined by the animal’s weight. Animals were not injected if they decreased below 
90% of their initial body weight; injections were resumed when weight was regained. 
VCD injections were administered on a four-day on, three-day off regimen to allow 
subjects to recover weight lost, and were completed over the course of one month. 
Water radial-arm maze retests. Following the initial training on the WRAM 
task and subsequent VCD or Vehicle administration, all subjects were given a two-day 
refresher on the WRAM, with procedures and platform locations identical to the initial 
training session. Immediately following two days of practice, the first WRAM retest took 
place. Each retest lasted two days. A total of nine retests occurred every other week for 
four months. Because ovarian failure from VCD takes approximately three months from 
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the first injection (Mayer et al., 2002, 2004), these retests captured behavioral snapshots 
throughout the transition into the follicle-deplete state, as well as the normal aging 
process in Vehicle-treated groups.  
Water radial-arm maze flexibility task. Following the final WRAM retest, 
subjects completed a flexibility task for five days. Animals were tested in the same room 
as WRAM, but received two new platform locations and two familiar platform locations, 
as schematically represented in Figure 2b. All other maze procedures were identical to 
previous WRAM testing. 
Morris water maze. After one day of rest, all subjects were evaluated for spatial 
reference memory using the win-stay Morris water maze (MM; Figure 2c). The apparatus 
was a large round tub (188 cm diameter) filled with black-tinted water maintained at 18-
20°C. One platform (11 cm diameter) was hidden just below the surface of the water in 
the northeast quadrant of the maze. This platform location remained constant across all 
days and trials. Salient spatial cues were present around the room to aid in spatial 
navigation to the platform (Morris et al., 1982). Each subject received four trials per day 
for five days. At the beginning of each trial, animals were dropped off from one of four 
starting points (north, south, east, or west) in a semi-randomly determined order. Drop off 
points also varied semi-randomly across days. Animals had 60 seconds to locate the 
platform before the experimenter led them to it. Once the platform was found, the rat 
remained on the platform for 15 seconds to allow for spatial localization before the 
experimenter returned it to the heated testing cage for an ITI of five to eight minutes. On 
the final day of MM, animals were given an additional probe trial in which the 
submerged platform was removed from the maze and animals swam freely in the maze 
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for 60 seconds. The probe trial was implemented to evaluate whether the animals had 
spatially localized to the platform by quantifying the swim distance in the target quadrant 
versus the opposite quadrant. A video camera and tracking system (Ethovision; Noldus 
Instruments; Wageningen, The Netherlands) were utilized to measure each rat’s swim 
path (distance in cm) across all days and trials, as well as on the probe trial. 
Visible platform. After one day of rest, subjects were tested on the Visible 
Platform (VP) task as a measure of visual and motoric competency. This is a non-spatial 
adaptation of the cue-navigation version of the spatial MM, which has been used to 
dissociate visual and motor acuity from place memory (Morris et al., 1982). The 
apparatus was a rectangular tub (100 x 60 cm) filled with clear water maintained at 18-
20°C. A black platform (10 cm diameter) was placed 4 cm above the surface of the water. 
Opaque curtains were hung around the room to block out any potential spatial or 
geometric cues (Figure 2d). Subjects were given six trials in one day. Animals were 
dropped off from a fixed location, while the platform location varied semi-randomly in 
three possible locations across trials. Each subject had 90 seconds to locate the platform, 
and was allowed to remain on the platform for 15 seconds before being returned to its 
heated home cage for an ITI of five to eight minutes.  
Sacrifice 
Subset Sacrifice: 
A subset of animals (n=3/group) was sacrificed on Day 52 of follicular depletion 
(i.e. approximately two-thirds of the way to a follicle-deplete state). This subset is 
representative of the early menopause transition time point, wherein immature ovarian 
follicles are undergoing extensive atresia leading to a follicle-deplete state (Mayer et al., 
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2002, 2004). Procedures for the subset sacrifice and end sacrifice were identical and are 
described below. 
End Sacrifice: 
Three additional animals died over the course of the study. The remaining 
subjects (N=41) were sacrificed one day after the final behavioral measure to obtain 
blood, ovaries, uterine weights, and brains for analysis. Rats were deeply anesthetized 
with isoflurane anesthesia. Blood was collected via cardiocentesis prior to decapitation. 
Brains were rapidly removed and blocked posterior to the basal forebrain. The anterior 
portion of the brain was immediately transferred to and fixed in 4% paraformaldehyde for 
48 hours, and then transferred to 0.1 M phosphate buffered solution (PB, pH 7.4) until 
future analysis. Tissues from the dorsal hippocampus, ventral hippocampus, entorhinal, 
and perirhinal cortices were raw dissected immediately following brain extraction. Each 
sample was placed in a pre-weighed microcentrifuge tube, weighed, immediately frozen 
on dry ice, and subsequently stored at -70°C until future analysis. Uterine horns and 
ovaries were dissected from the body cavity. Ovaries were removed from the tips of the 
uterine horn, trimmed of excess fat, and fixed in 4% paraformaldehyde until analysis. 
Uterine horns were trimmed of visible fat and wet weight was obtained as a marker of 
gonadal hormone stimulation.  
Serum Hormone Radioimmunoassay. At sacrifice, blood was collected via 
cardiocentesis prior to decapitation to assay 17β-Estradiol, Androstenedione, 
Progesterone, and Estrone serum levels. Blood was allowed to clot at 4°C (Vacutainer 
367986, Becton Dickinson and Company, Franklin Lakes, NJ, USA). Serum was 
collected after centrifugation for 20 minutes at 4°C. Serum was stored at -20°C until 
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assays were performed. Serum hormone levels were determined by radioimmunoassay 
using previously described methods (Acosta et al., 2010; Camp et al., 2012; Mennenga et 
al., 2015a, 2015b).  
Briefly, 17β-estradiol was determined using a double antibody liquid-phase 
radioimmunoassay purchased from Beckman Coulter (Brea, CA), that employs estradiol-
specific antibodies along with a 125I-labeled estradiol as the tracer. Interassay 
coefficients of variation for the assay average 8% at a mean value of 6 pg/ml. Functional 
sensitivity of the assay is 4 pg/ml.  
Estrone was determined using a double antibody liquid-phase radioimmunoassay 
purchased from Beckman Coulter (Brea, CA), that employs estrone-specific antibodies 
along with an 125I-labeled estrone as the tracer. Interassay coefficients of variation for 
the assay average 11% at a mean value of 90 pg/ml. Functional sensitivity of the assay is 
16 pg/ml.  
Androstenedione was determined using a solid-phase radioimmunoassay 
purchased from Siemens (Los Angeles, CA), based on androstenedione-specific 
antibodies that are immobilized to the wall of polypropylene tubes and 125I-labeled 
androstenedione as the tracer. Interassay coefficients of variation for the assay average 
3% at a mean value of 2.80 ng/ml. Functional sensitivity of the assay is 0.1 ng/dl.   
Progesterone was determined using a solid-phase radioimmunoassay, based on 
progesterone-specific antibodies that are immobilized to the wall of polypropylene tubes 
and 125I-labeled progesterone as the tracer. Interassay coefficients of variation for the 
assay average 4% at a mean value of 3.3 ng/ml. Functional sensitivity of the assay is 0.1 
ng/ml.  
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Ovarian Follicle Counts. After fixing ovaries in 4% paraformaldehyde after 
sacrifice, one ovary from each subject was randomly selected for processing and 
quantification of primordial, primary, secondary, and antral follicles, as well as corpora 
lutea. Primordial follicles are considered to be non-growing, or resting-state, follicles 
within the ovary; they are the ovarian reserve, as well as the follicles specifically targeted 
by VCD. Primary ovarian follicles are often grouped with primordial cells as part of the 
ovarian reserve (Hansen et al., 2008), and are also small, preantral follicles affected by 
VCD-treatment (Dyer et al., 2013; Hu et al., 2001a, b; Kao et al., 1999; Mayer et al., 
2002, 2004; Springer et al., 1996c). Secondary follicles are part of the growing follicle 
pool, exhibit thecal cells, and are an intermediate stage between recruitment of the 
follicle and maturation to a pre-ovulatory antral follicle (also referred to as a Graafian 
follicle), which is a large follicle containing a fluid-filled antrum that has the potential to 
be recruited for ovulation when the LH surge occurs. After ovulation occurs, the 
remaining follicle undergoes morphological changes to become a temporary endocrine 
structure called the corpus luteum, which secretes Progesterone in preparation for 
potential fertilization; if fertilization does not occur, the corpus luteum degenerates 
(Hirshfield, 1991; Kronenberg et al., 2008). Figure 3 provides a schematic of ovarian 
follicle types and corpora lutea.  
Ovarian tissues were processed for paraffin embedding, sectioned at 5 µm, 
mounted, and stained with hematoxylin and eosin Y-phloxine B. Primordial, primary, 
secondary, and antral follicles were counted for every 20th section. Corpora lutea were 
counted at a magnification of 10x (Spencer compound microscope; American Optical, 
Buffalo, NY). The total number of follicles was calculated using the following formula: 
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Nt = (N0 x St x ts) / (S0 x d0), where Nt = total calculated number of follicles, N0 = 
number of follicles observed in the ovary, St = total number of sections in the ovary, ts = 
thickness of the section (µm) S0 = total number of sections observed, and d0 = mean 
diameter of the nucleus (Gougeon and Chainy, 1987). Ovarian follicle stage was 
determined using criteria from Haas et al., 2007. Briefly, primordial cells were denoted 
by the presence of a single layer of squamous granulosa cells surrounding an oocyte. 
Primary follicles presented with a single layer of cuboidal granulosa cells. Secondary 
follicle classification required several granulosa cell layers. Antral follicles were defined 
as having two or more layers of granulosa cells as well as a fluid-filled antral space 
within the follicle (Hass et al, 2007).  
Statistical Analyses 
All data analyses were completed using SPSS 23 software. Two group 
comparisons were set a priori to compare treatment effects within each age group to 
determine if young animals respond differently than middle-aged animals to the onset of 
VCD-induced follicular depletion. Additionally, planned comparisons were set to 
compare age effects within each treatment group to evaluate the impact of menopause 
induction in young and middle-aged animals. Finally, planned comparisons were 
designated to evaluate performance on trial four of the water radial-arm maze, as working 
memory is increasingly taxed as trials progress, and previous research indicates that in 
many cases differences emerge on high working memory load trials (Bimonte & 
Denenberg, 1999; Bimonte-Nelson et al., 2003, 2004; Braden et al., 2010; Mennenga et 
al., 2015b). Unless otherwise noted, two-tailed tests were used with an alpha level set at 
0.05. 
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Behavior data.  
Water radial-arm maze. Raw error scores from the WRAM were log transformed 
to account for extreme scores and the negative skew of error distribution as trials progress 
(Cohen et al., 2003). Log transformed scored were calculated by adding one to each raw 
data point, and then calculating the natural log of that adjusted score. Log transformed 
data were utilized in the following analyses for the WRAM.  
WRAM training data were analyzed using a nested repeated-measures ANOVA 
design with Age as the independent variable, and Days and Trials as repeated measures. 
The dependent measure was Total Errors committed. WRAM refresher and retest data 
were also analyzed for Total Errors, utilizing a nested repeated-measures ANOVA design 
with Age (Young or Middle-Aged) and Treatment group (Vehicle or VCD) as the 
independent variables, and Retest, Days, and Trials as repeated measures. Each retest was 
assessed separately, with Days and Trials as the repeated measures variables, where four 
trials with increasing memory load occurred within each day of the retest period. The 
Huynh-Feldt correction was applied to repeated measures data to account for potential 
violations of sphericity by altering degrees of freedom (but not the F-ratio) to reduce 
Type I error rate as a result of repeated measures analyses (Huynh & Feldt, 1976). Four 
animals were excluded for health-related concerns, and three animals were excluded from 
all analyses due to extreme outlying scores that were greater than two standard deviations 
from the mean of the group’s performance when compared to other subjects for WRAM 
performance. Three animals were excluded because they died prior to the completion of 
the study.  
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Water radial-arm maze flexibility task. Data analyses were identical to the 
WRAM analyses described above, with log transformation, Age and Treatment as 
between-subjects factors, Days and Trials as repeated measures, and Total Errors as the 
dependent variable.  
Morris water maze. Data were analyzed using repeated-measures ANOVA where 
Age (Young or Middle-Age) and Treatment (Vehicle or VCD) were used as the 
independent variables, and Days and Trials as repeated measures, where four trials per 
day occurred within each of the five days. The dependent measure assessed was Swim 
Distance (cm) to the platform. Because several animals were lost to attrition and excluded 
for health-related concerns at this time point, a repeated-measures ANCOVA using the 
sum of total errors committed on the final day of training (prior to treatment) as the 
covariate to account for pre-existing differences in animals’ performance was also 
performed for the Swim Distance analysis. The probe analysis used percent of total Swim 
Distance (cm) in the Target versus Opposite Quadrant as the dependent measure.  
Visible platform task. Visible platform data were analyzed using repeated-
measures ANOVA with Age and Treatment as the independent variables, and latency to 
platform (s) as the dependent measure, with trials as the repeated measure. 
Ovarian follicle and serum hormone level data. Two-way ANOVA was 
utilized for ovarian follicle count data. Independent variables were Age and Treatment, 
and dependent variables included ovarian follicle counts of primordial, primary, 
secondary, and antral follicles, as well as corpora lutea. Two-way ANOVA was also 
utilized for serum hormone level data. Independent variables were Age and Treatment, 
and dependent variables included 17β-Estradiol, Androstenedione, Progesterone, and 
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Estrone levels. Unless otherwise noted, two-tailed tests were used with an alpha set at 
0.05. 
Results 
Water Radial-Arm Maze Training 
The ANOVA for Total Errors including all young and middle-aged animals prior 
to treatment administration across all days of training revealed a main effect of Age 
[F(1,44)=4.12, p<0.05], where Middle-Aged animals made more errors than Young 
animals collapsed across all days of testing (Figure 4a). There was also a main effect of 
Day [F(10,445)=29.83, p<0.01], such that animals decreased in errors across days of testing, 
and a main effect of Trial [F(3,129)=277.64, p<0.01], wherein errors increased as trials 
progressed and working memory load increased.  
Previous studies examining the impact of gonadal hormones on spatial memory 
have observed marked effects on the WRAM when working memory load is taxed 
(Bimonte & Denenberg, 1999; Bimonte-Nelson et al., 2003, 2004; Braden et al., 2010). 
Working memory load effects often present in the latter part of testing, or the asymptotic 
phase, after animals have learned the rules of the task (Bimonte & Denenberg, 1999; 
Bimonte et al., 2000, 2003; Hyde et al., 2000; Mennenga et al., 2015b). Therefore, we 
assessed performance for a block comprised of the last six days of testing (Days 7-12). 
For this block, there was a marginal main effect of Age [F(1,44)=3.877, p=0.06]. Each trial 
for the Day 7-12 block was assessed separately, and we found that there was a main 
effect of Age on Trial 3 [F(1,44)=5.58, p<0.05], where the Middle-Aged group made more 
errors than the Young group (Figure 4b). However, by Trial 4, there was no longer an 
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Age effect [F(1,44)=1.354, p=NS], indicating that the working memory load on Trial 4 was 
sufficiently difficult to challenge both young and middle-aged animals.  
Water Radial-Arm Maze Retests 
Refresher practice. After initial WRAM training and then one month of Vehicle 
or VCD injections, animals received two days of refresher practice on the WRAM, 
utilizing the same respective platform locations each animal previously learned during 
training, one month prior to starting the retest sessions. Performance was evaluated 
within each treatment group from the last day of training (prior to treatment 
administration) to the first day of the refresher practice block (after treatment) to assess 
forgetting over the one-month interim. For the Young Vehicle-treated group, there was 
no effect of Day [F(1,11)=2.72, p=NS], suggesting that during the one-month interval 
where these animals received Vehicle injections, they retained memory for their four 
assigned platform locations. However, the Young VCD-, Middle-Aged Vehicle-, and 
Middle-Aged VCD- treated groups had a main effect of Day (Young-VCD: [F(1,10)=8.76, 
p<0.05; Middle-Aged Vehicle: [F(1,9)=15.72, p<0.01]; Middle-Aged VCD: [F(1,12)=13.69, 
p<0.01]) with errors increasing across the training to refresher interval, indicating 
forgetting across the month in which they received their treatment (Figure 5). The 
collected results from the refresher indicate that initiation of follicular depletion impacted 
the Young group’s ability to remember platform locations learned a month ago as 
compared to Vehicle-treated counterparts, and that Middle-Aged animals exhibited 
forgetting across the month delay regardless of treatment. 
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Water radial-arm maze retests. 
Evaluating whether follicular depletion across the menopause transition 
impacts young and middle-aged animals differently. To evaluate how each age group 
responded to VCD-induced follicular depletion compared to age-matched Vehicle-treated 
animals, planned comparisons were performed within the Young cohort and within the 
Middle-Aged cohort. Retests 1 and 2 were combined into a single block representing the 
early menopause transition period. During this block, two group (Vehicle vs. VCD) 
planned comparisons for Young animals revealed a main effect of Treatment 
[F(1,21)=10.32, p<0.01], with Young-VCD animals making more errors than Young-
Vehicle animals, as well as a Trial x Treatment interaction [F(3,63)=3.56, p<0.05], with 
Young-VCD animals making disproportionately more errors as trials, and working 
memory load, increased, as compared to Young-Vehicle animals. Indeed, on Trial 4, the 
highest working memory load trial, the Young VCD-treated group made more errors than 
the Young Vehicle-treated group [F(1,21)=15.93, p<0.01] (Figure 6a). Planned 
comparisons for the Middle-Aged cohort showed neither a main effect of Treatment 
[F(1,21)=0.61, p=NS] nor a Trial x Treatment interaction [F(2,46)=0.07, p=NS]. Moreover, 
Middle-Aged Vehicle- and Middle-Aged VCD-treated groups did not differ in 
performance on Trial 4 [F(1,21)=0.22, p=NS] (Figure 6b). 
 Following this initial early menopause transition block, no differences were 
observed in the planned comparisons within the Young cohort and within the Middle-
Aged cohort on retests three through nine, indicating that VCD-induced follicular 
depletion had a transient impairing effect on spatial memory for young animals, but not 
middle-aged animals, early in the menopause transition.  
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Evaluating whether follicular depletion influences age effects on cognition. 
Another goal of the study was to evaluate whether menopause exacerbates age-related 
changes in spatial memory performance. Therefore, we compared Young and Middle-
Aged animals within the Vehicle-treated cohort and within the VCD-treated cohort. 
During the early menopause transition block (Retest 1 and 2), a marginal main effect of 
Age was observed for Vehicle-treated animals [F(1,20)=3.56, p=0.07], where Middle-Aged 
Vehicle-treated animals made marginally more errors than Young Vehicle-treated 
animals (Figure 6c). For VCD-treated animals, an age effect was not observed, indicating 
that Young VCD-treated animals performed similarly to Middle-Aged VCD-treated 
animals (Figure 6d).  
Although no differences were observed on Retest 3, on Retest 4, as the VCD-
treated cohort transitioned to a follicle deplete state, we observed that for VCD-treated 
animals, there was a main effect of Age [F(1,16)=5.38, p<0.05] and an Age x Trial 
interaction [F(3,48)=2.77, p=0.05]. On Trial 4, for animals that received VCD, Middle-
Aged animals made more errors than Young animals [F(1,16)=8.75, p<0.01], indicating 
that VCD-induced follicular depletion imparted an age effect (Figure 7b). On the other 
hand, for the Vehicle-treated cohort, there was neither a main effect of Age [F(1,14)=2.21, 
p=NS] nor an Age x Trial interaction [F(2,23)=1.11, p=NS]. On Trial 4, there was no Age 
effect for animals that received Vehicle treatment (Figure 7a). Thus, menopause 
induction imparted an age effect that was not seen in Vehicle-treated animals.  
 No age effects were observed on Retests 5, 6, 7, or 8 within each treatment 
cohort. On Retest 9 –well into the post-menopause time point– for VCD-treated animals, 
there was a main effect of Age [F(1,16)=4.34, p=0.05]. On Trial 4, there was a marginal 
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Age effect for animals that received VCD-induced follicular depletion, whereby Middle-
Aged animals made marginally more errors than Young animals [F(1,16)=3.42, p=0.08], 
indicating that VCD-induced follicular depletion marginally imparted an age effect in the 
post-menopausal time point (Figure 8b). For Vehicle-treated animals, there was no main 
effect of Age [F(1,14)=1.27, p=NS] and no observed differences in performance on Trial 4 
(Figure 8a).  
Water Radial-Arm Maze Flexibility Task 
After Retest 9, platform location assignments were altered for all subjects; two of 
their assigned locations remained the same, and two locations were changed to different 
arms, such that there were two familiar and two novel platform locations for this task.  
Evaluating whether follicular depletion impacts cognitive flexibility in young 
and middle-aged animals differently. From the last day of Retest 9 to the first day of the 
WRAM Flexibility task, there was a main effect of Day for the Young cohort 
[F(1,15)=80.14, p<0.01] as well as for the Middle-Aged cohort [F(1,15)=30.97, p<0.01] 
wherein all subjects made more errors on the day of the flip, regardless of Vehicle or 
VCD treatment (Figure 9). Across the five days of flipped testing, there was a main effect 
of Day (Young: [F(3,52)=12.96, p<0.01]; Middle-Aged: [F(4,60)=13.28, p<0.01]) indicating 
that all animals learned across the testing period (Figure 9a-b). On the final day of the 
flexibility task, for the Middle-Aged cohort, there was a marginal main effect of 
Treatment [F(1,15)=3.97, p=0.07], where VCD-treated animals made more errors than 
Vehicle-treated counterparts, suggesting that follicular depletion in middle-aged animals 
results in poorer performance compared to Vehicle-treated counterparts for a flexibility 
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measure (Figure 9b); however, the Young cohort did not differ in performance, regardless 
of ovarian status. 
Evaluating whether follicular depletion influences age effects for cognitive 
flexibility. From the last day of Retest 9 to the first day of the WRAM Flexibility task, 
there was a main effect of Day for the Vehicle cohort [F(1,14)=50.28, p<0.01] as well as 
for the VCD cohort [F(1,16)=51.64, p<0.01] wherein all subjects made more errors on the 
day of the flip, regardless of age (Figure 9). Across the five days of testing, there was a 
main effect of Day (Vehicle: [F(3,56)=14.55, p<0.01]; VCD: [F(4,64)=10.54, p<0.01]) 
indicating that all animals learned across the testing period. On the final day of the 
flexibility task, in the VCD cohort there was a marginal main effect of Age [F(1,16)=3.52, 
p=0.08] where older animals made more errors than younger animals; of note, this age 
effect did not occur in the Vehicle cohort. Again, we see that follicular depletion 
exacerbated memory deficits in middle-aged, but not young, animals, while there were no 
age effects in animals that did not undergo follicular depletion (Figure 9c-d).  
Morris Water Maze 
Evaluating whether follicular depletion impacts memory performance on a 
novel reference memory task in young and middle-aged animals differently. To 
evaluate how each age group responded to VCD-induced follicular depletion compared to 
age-matched Vehicle-treated animals, planned comparisons were performed within the 
Young cohort and within the Middle-Aged cohort. For the Young cohort, across the five 
days of testing, there were no Treatment differences. There was a main effect of Day 
[F(4,60)=74.85, p<0.01] indicating learning across days for all Young animals (Figure 
10a). Planned comparisons for Middle-Aged animals revealed a main effect of Treatment 
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[F(1,15)=5.24, p<0.05], where VCD-treated animals had a lower swim distance compared 
to Vehicle-treated counterparts, indicating that ovarian follicle depletion occurring in 
middle-age may aid reference memory for a novel task as compared to non-follicle 
deplete animals of the same age. There was also a main effect of Day [F(4,60)=37.62, 
p<0.01] demonstrating learning across days for all Middle-Aged animals (Figure 10b). A 
covariate of WRAM performance prior to treatment was also utilized to control for any 
pre-existing differences in performance. The effects seen in the original repeated 
measures ANOVA analysis were upheld with the presence of the covariate: (Young 
cohort: Day: [F(4,56)=34.57, p<0.01]; Middle-Aged cohort: Treatment [F(1,14)=4.60, 
p=0.05], Day [F(4,56)=9.48, p<0.01]). 
Overnight forgetting was assessed as a measure of memory retention for a 
reference memory task during an overnight interval. We collapsed across the last trial of 
each day (Trial 4) and the first trial of each day (Trial 1). For Middle-Aged animals, there 
was a marginal Trial x Treatment interaction [F(1,15)=3.52, p=0.08], where on the first 
trial of the day, Middle-Aged VCD-treated animals had a lower swim distance than 
Vehicle-treated counterparts [F(1,15)=4.32, p=0.06]. There were no treatment differences 
between Young groups for overnight forgetting. 
Evaluating whether follicular depletion influences age effects for a novel 
reference memory task. We also aimed to evaluate the impact of each type of 
reproductive senescence in young and middle-aged animals. Therefore, planned 
comparisons were completed for each treatment group. For the Vehicle-treated cohort, 
across the five days of MM testing, there were no Age differences. There was a main 
effect of Day [F(4,56)=41.98, p<0.01] indicating learning across days for all Vehicle-
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treated animals (Figure 10c). Planned comparisons for the VCD-treated cohort revealed a 
main effect of Age [F(1,16)=5.42, p<0.05], where Young animals had less swim distance 
compared to Middle-Aged animals. There was also a main effect of Day [F(4,64)=63.75, 
p<0.01] indicating learning across days for all VCD-treated animals (Figure 10d). A 
covariate of WRAM performance prior to treatment was also utilized to control for any 
pre-existing differences in performance. The effect of learning across days seen in the 
original repeated measures ANOVA analysis was upheld with the presence of the 
covariate: (Vehicle cohort: Day [F(4,52)=10.93, p<0.01]; VCD cohort: Day [F(4,60)=24.71, 
p<0.01]). Within the VCD cohort, the effect of Age became marginal when the covariate 
was included in the analysis for Swim Distance [F(1,15)=3.38, p=0.09], suggesting that 
when controlling for earlier performance on another task, the observed differences 
between the Middle-Aged- and Young- VCD-treated animals decrease. 
 Overnight forgetting planned comparisons did not reveal effects of Age in either 
Vehicle- or VCD-treated cohorts.  
Probe trial performance. Each treatment group was assessed separately for 
performance on the probe trial. Results indicated that there was a main effect of Quadrant 
for each group (Young-Vehicle: [F(1,8)=35.09, p<0.01], Young-VCD: [F(1,7)=49.60, 
p<0.01], Middle-Aged-Vehicle: [F(1,6)=29.43, p<0.01], Middle-Aged-VCD: [F(1,9)=79.64, 
p<0.01]), indicating that all animals, regardless of treatment or age, had a greater percent 
of total swim distance in the target quadrant; that is, they all localized to the northeast 
quadrant where the platform was previously located versus the opposite, southwest 
quadrant (Figure 11).  
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Visible Platform 
There was a main effect of Trial [F(3,93)=9.341, p<0.01] such that all animals 
decreased latency to find the visible platform (s) across the six trials. By Trial 6, all 
animals, regardless of age or treatment, found the visible platform in an average of 5.72s 
(Figure 12).  
Serum Hormone Levels 
Serum hormone levels for 17β-Estradiol, Estrone, Progesterone, and 
Androstenedione were obtained for animals at the subset sacrifice time point and the end 
sacrifice time point. Tables 1-4 include the mean ± SE, range, and median values for each 
hormone at each time point. Planned comparisons were completed within the Young 
cohort, the Middle-Aged cohort, the Vehicle cohort, and the VCD cohort.  
Subset sacrifice. Middle-Aged animals (VCD: n=3; Vehicle: n=3) were 14 mo 
and Young animals (VCD: n=3; Vehicle: n=3) were 8 mo at serum analysis for the subset 
sacrifice.  
Evaluating whether follicular depletion impacts circulating ovarian hormone 
levels in young and middle-aged animals differently at the subset sacrifice time 
point. There were no differences within the Young cohort or within the Middle 
Aged cohort for 17β-Estradiol, Estrone, or Progesterone levels during the subset 
sacrifice. For Androstenedione levels in the Young cohort, there was a marginal main 
effect of Treatment [F(1,4)=4.71, p=0.096], where Vehicle-treated animals had marginally 
more Androstenedione than VCD-treated animals (Figure 13c).  
Evaluating whether follicular depletion influences age effects on circulating 
ovarian hormone levels at the subset sacrifice time point. There were no differences 
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within the Vehicle cohort or the VCD cohort for 17β-Estradiol or Estrone. For 
Androstenedione levels in the VCD-treated cohort, there was a main effect of Age 
[F(1,4)=7.50, p=0.05], wherein Middle-Aged animals had higher Androstenedione levels 
than Young animals (Figure 13c). For the Vehicle-treated cohort, there were no Age 
effects for Androstenedione levels. For Progesterone in the VCD-treated cohort, there 
was a main effect of Age [F(1,4)=11.24, p<0.05], where Middle-Aged animals had more 
Progesterone than Young animals (Figure 13d); however, there were no differences in 
Progesterone levels for the Vehicle cohort at the subset sacrifice time point.  
End sacrifice. Animals that were excluded for behavioral analyses were also 
excluded from serum analyses. Middle-Aged animals (VCD: n=10; Vehicle: n=7) were 
18 mo and Young animals VCD: n=8; Vehicle: n=9) were 12 mo at the end sacrifice 
serum analysis. Of note, for the Estrone hormone assay, seven animals did not have a 
sufficient serum quantity to complete the assay, and for the Androstenedione hormone 
assay, three animals did not have a sufficient serum quantity to complete the assay. 
Evaluating whether follicular depletion impacts circulating ovarian hormone 
levels in young and middle-aged animals differently at the end sacrifice time point. 
There were no differences within the Young cohort or within the Middle-Aged cohort for 
17β-Estradiol or Androstenedione levels at the end sacrifice. For Estrone levels, within 
the Young cohort as well as within the Middle-Aged cohort, there was a marginal main 
effect of Treatment (Young: [F(1,11)=3.62, p=0.08]; Middle-Aged: [F(1,12)=4.31, p=0.06]; 
Figure 13f), where VCD-treated animals had less Estrone compared to Vehicle-treated 
animals. For Progesterone levels within the Young cohort as well as within the Middle-
Aged cohort, there was a main effect of Treatment (Young: [F(1,15)=6.98, p<0.05]; 
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Middle-Aged: [F(1,15)=12.35, p<0.01]; Figure 13h) wherein VCD-treated animals had less 
Progesterone than Vehicle-treated animals.  
Evaluating whether follicular depletion influences age effects on circulating 
ovarian hormone levels at the end sacrifice time point. There were no age differences 
within the Vehicle cohort or the VCD cohort for 17β-Estradiol, Estrone, or Progesterone 
levels. For Androstenedione levels within the Vehicle cohort, there was a marginal main 
effect of Age [F(1,12)=3.97, p=0.07] wherein Middle-Aged animals had more 
Androstenedione than Young animals (Figure 13g). However, within the VCD cohort, 
there were no age differences in Androstenedione levels, indicating that younger VCD-
treated animals have similar Androstenedione levels to older VCD-treated animals.  
Ovarian Follicle Counts 
Ovarian follicle counts were obtained for both subset and end sacrifices. Quantification 
of ovarian follicles were divided into the following stages: primordial, primary, 
secondary, and antral follicles; corpora lutea were also quantified. Figure 3 shows a 
schematic of the stages of ovarian follicle development. 
Subset sacrifice. 
Evaluating whether follicular depletion impacts ovarian follicle counts in 
young and middle-aged animals differently at the subset sacrifice time point. Within the 
Young cohort there was a main effect of Treatment for primordial cells [F(1,4)=26.40, 
p<0.01], primary cells [F(1,4)=14.30, p<0.05], secondary cells [F(1,4)=10.98, p<0.05], and 
antral cells [F(1,4)=28.80, p<0.01], where VCD-treated animals had fewer ovarian follicles 
of each subtype than Vehicle-treated counterparts (Figure 14a-d). Within the Middle-
Aged cohort there was a main effect of Treatment for primordial cells [F(1,4)=27.01, 
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p<0.01] and a marginal main effect of Treatment [F(1,4)=6.42, p=0.06] for primary cells, 
with VCD-treated animals having fewer cells than Vehicle-treated counterparts (Figure 
14a-b). The Middle-Aged cohort did not have an observed difference in secondary or 
antral follicles at the subset time point. There were no observed differences in the number 
of corpora lutea in either the Young cohort or the Middle-Aged cohort at this time point. 
Evaluating whether follicular depletion influences age effects on ovarian 
follicle loss at the subset sacrifice time point. Within the Vehicle cohort, there was a 
marginal main effect of Age [F(1,4)=5.50, p=0.08], where Young animals had more 
primordial follicles than Middle-Aged animals (Figure 14a). There were no differences in 
primary, secondary, or antral follicles for the Vehicle cohort. Within the VCD cohort 
there were no differences in any ovarian follicle subtype. Neither the Vehicle cohort nor 
the VCD cohort exhibited differences in corpora lutea at this time point.  
End sacrifice. 
Evaluating whether follicular depletion impacts ovarian follicle counts in 
young and middle-aged animals differently at the end sacrifice time point. Within the 
Young cohort, there was a main effect of Treatment for primordial follicles [F(1,15)=25.12, 
p<0.01], primary follicles [F(1,15)=34.72, p<0.01], secondary follicles [F(1,15)=27.44, 
p<0.01], antral follicles [F(1,15)=16.31, p<0.01], and corpora lutea [F(1,15)=200.89, 
p<0.01], where VCD-treated animals had fewer ovarian follicles and corpora lutea than 
Vehicle-treated counterparts. Within the Middle-Aged cohort, there was also a Treatment 
effect observed for primordial follicles [F(1,15)=4.79, p<0.05], primary follicles 
[F(1,15)=63.57, p<0.01], secondary follicles [F(1,15)=61.45, p<0.01], antral follicles 
[F(1,15)=41.36, p<0.01], and corpora lutea [F(1,15)=241.00, p<0.01], where VCD-treated 
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animals had fewer ovarian follicles and corpora lutea than Vehicle-treated counterparts 
(Figure 14f-j). In sum, VCD treatment effectively reduced ovarian follicle number in both 
age groups compared to Vehicle treatment.  
Evaluating whether follicular depletion influences age effects on ovarian 
follicle loss at the end sacrifice time point. Within the Vehicle cohort, there was a 
marginal effect of Age [F(1,14)=3.80, p=0.07] for primordial follicles, where Young 
animals had marginally more primordial follicles than Middle-Aged animals (Figure 14f). 
In addition, for Vehicle-treated animals a main effect of Age was revealed for primary 
follicles [F(1,14)=10.00, p<0.01] and secondary follicles [F(1,14)=5.34, p<0.05], where 
Young animals had more of these follicle subtypes than Middle-Aged animals. However, 
there were no effects of Age for antral follicles or corpora lutea in the Vehicle cohort. 
Within the VCD cohort, there were no effects of Age on primordial follicles, primary 
follicles, secondary follicles, or antral follicles, suggesting that VCD reduced the number 
of follicles in the ovary without interactions with age. It is of note that none of the VCD-
treated animals had quantifiable antral follicles at this time point, suggesting that these 
animals were no longer experiencing a normal ovarian cycle. However, within the VCD-
treated animals, there was a marginal main effect of Age for corpora lutea counts 
[F(1,16)=3.66, p=0.07] where Middle-Aged-VCD-treated animals had marginally more 
corpora lutea than Young-VCD-treated animals (Figure14f-j). These collective results 
provide evidence for age-related follicle decline in Vehicle-treated rats, as well as 
substantial atresia of ovarian follicles in VCD-treated subjects. 
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Correlations 
Correlations were performed between 17β-Estradiol, Estrone, Progesterone, and 
Androstenedione serum hormone levels and performance on MM, as this was the last 
spatial task prior to sacrifice. Correlations were also examined between Trial 4 of the last 
Retest completed on WRAM prior to sacrifice to determine if circulating gonadal 
hormone levels were related to working memory performance at the highest working 
memory load.  
 Total Swim Distance collapsed across all days of MM negatively correlated with 
serum Estrone levels for Middle-Aged VCD-treated animals only (r=-0.73, R2=0.53, 
p<0.05), where higher Estrone levels were associated with less overall swim distance, 
and therefore better performance (Figure 15). No correlations were significant for 17β-
Estradiol, Androstenedione, or Progesterone for Total Swim Distance collapsed across all 
days of MM. 
 Our laboratory has previously reported that higher circulating 17β-Estradiol levels 
positively correlate with better spatial localization to the target quadrant that previously 
contained the platform, as assessed during the MM probe trial, for young and middle-
aged Ovx females receiving tonic 17β-Estradiol treatment (Talboom et al., 2008). Here, 
we find a concordant effect of an overall positive correlation (with all groups included) 
between serum 17β-Estradiol levels and percent swim distance in the target quadrant 
during the probe trial (r=0.37, R2=0.14, p<0.05; Figure 16a). Each cohort was also 
evaluated separately, and a positive correlation was revealed between serum 17β-
Estradiol levels and the percent distance swam in the northeast (target) quadrant during 
the probe trial for Middle-Aged animals only (Vehicle: r=0.83, R2=0.69, p<0.05; VCD: 
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r=0.71, R2=0.51, p<0.05; Figures 16b-c). For Middle-Aged VCD-treated animals only, 
there was also a strong positive correlation between serum Estrone levels and quadrant 
localization during the probe trial (r = 0.85, R2=0.72, p<0.01), where higher Estrone 
levels were associated with a greater proportion of total swim distance in the target 
quadrant that previously contained the platform (Figure 16d); this correlation was not 
significant for the other groups. 
Overall, a marginal positive correlation occurred between Estrone levels and 
Total Errors on trial four of the WRAM (r=0.28, R2=0.08, p=0.08) where higher 
circulating Estrone levels were associated with more errors on trial four of the WRAM 
(Figure 17). No significant correlations emerged overall or within individual treatment 
groups for other circulating ovarian hormone levels. 
Uterine Horn Weights 
There were no main effects of Age or Treatment on uterine horn wet weight (g) at 
either sacrifice time point. All uterine horns were similar in weight regardless of 
treatment. Given that 17β-Estradiol has a well-known stimulatory effect on uterine tissue 
growth (Brody & Wiqvist, 1961; Kang et al., 1975) and there were no differences in 
circulating 17β-estradiol levels, this result was expected. 
Discussion 
Here, we performed a longitudinal study evaluating independent and interactive 
effects of age and ovarian status on spatial memory performance across the transition to 
menopause in a rodent model. The collective results indicate that both the age at the 
beginning of the menopause transition and the depletion of the ovarian follicle pool play 
important roles in spatial memory performance and maintenance over time. Moreover, 
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the impact of age and follicular depletion on spatial memory manifests when the working 
memory system is highly taxed, as evidenced by the differences on trial four of the 
WRAM, when working memory load is the highest.  
Age and Menopause Effects on Spatial Memory 
The current study indicates that a younger age at the onset of follicular depletion 
negatively impacts spatial memory. Specifically, early in the transition to menopause 
(Retests 1 and 2), on the WRAM the Young VCD-treated animals were impaired 
compared to Vehicle-treated counterparts while the Middle-Aged animals perform 
similarly, regardless of Vehicle or VCD treatment. In the early stage of follicular 
depletion, induced transitional menopause resulted in a profile where younger animals 
performed similarly to middle-aged animals in terms of spatial memory performance on 
the WRAM, particularly on trial four, when the working memory load demand was 
highest. The memory impairment observed in the Young VCD-treated animals during 
this time point early in the transition to menopause suggests that undergoing the 
transition to menopause prior to middle-age may be detrimental to memory performance, 
and has significant implications when translating to the clinic. This early stage of the 
VCD menopause model involves substantial ovarian follicle decline, which is analogous 
to the beginning of the human menopause transition when many of the negative 
symptoms associated with menopause (i.e. vasomotor symptoms, sleep, affective, and 
memory changes) begin to present and women tend to report some memory complaints. It 
is particularly interesting that these changes occur in adult animals undergoing follicular 
depletion because advancing age is not a confounding factor for these animals. Indeed, 
their age-matched controls had significantly better performance on the task at the highest 
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working memory load, indicating that the induction of follicular depletion, and the 
hormonal and ovarian changes associated with it, appears to have a unique impact on 
adult animals that are not yet naturally transitioning to a reproductively senescent state. 
Providing insight into the dissociation between the effects of aging and follicular 
depletion is a tremendous benefit of using animal models, as these variables are difficult 
to evaluate independently in women because the onset of transitional menopause is 
typically concomitant with aging. This translational model suggests that in humans, the 
perturbation of a normally functioning hypothalamic-pituitary-gonadal axis prior to the 
average age of menopause onset, as is the case for early and premature onset of 
menopause, can result in disrupted performance on spatial working memory tasks. 
Currently, there are no definitive clinical markers for the onset of the menopause 
transition. Because the cognitive changes seen here in the animal model occur early in the 
transition, it is critical to develop reliable measures to establish the onset of the transition 
to reproductive senescence in women. This could afford the opportunity to intervene 
during a critical window of opportunity early in the transition to ascertain beneficial 
effects of hormone therapy administration on menopause-related memory changes.  
A series of retests were administered throughout the transition into a follicle-
deplete state. Following the early menopause time point, as the transition into menopause 
progressed, an age-related effect of follicular depletion became apparent. During Retest 4 
on the WRAM, which is considered a mid-menopause transition time point, the induction 
of follicular depletion amplified an age-related memory deficit, wherein Middle-Aged 
VCD-treated animals made more errors than Young VCD-treated animals, particularly at 
the highest working memory load trial. In the post-menopause transition time point of 
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Retest 9, this pattern of follicular depletion amplifying an age effect, though marginal, 
presented again. Thus, at two critical time points during the mid- and post- menopausal 
transition, older animals experiencing follicular depletion were impaired relative to 
younger animals with the same treatment, suggesting that as aging ensues concordant 
with follicular depletion, age-related impairments become evident. Translationally, 
because the average life span is increasing, it is of interest to potentially slow the rate of 
follicular depletion in order to prolong the positive effects of follicle-replete ovaries and 
normal circulating sex steroid hormone levels on memory as well as a myriad of other 
body systems. Perhaps novel hormone therapy options will be developed in order to 
extend the pre-menopausal life stage by slowing the rate of ovarian follicle reserve loss, 
such that follicular depletion amplification of age effects will be postponed until later in 
life.  
 In evaluating the WRAM flexibility task, all animals improved their performance 
across the five-day task. On the final day, older VCD-treated animals performed 
marginally worse than their age-matched Vehicle controls, indicating that in a post-
menopausal state, the loss of ovarian follicles has some impact on performance on a 
novel flexibility task. Within the VCD-treated cohort, a marginal age effect was 
observed, where older animals made more errors than younger animals; this effect did not 
occur within the Vehicle-treated cohort, indicating that follicular depletion may amplify 
age-related impairments for flexibility in learning and memory for a spatial task, similar 
to its impact on the WRAM task in the mid- and post- menopausal time points.  
Morris water maze results indicated that the younger animals learned the task 
similarly regardless of ovarian status. However, results indicated that the Middle-Aged 
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VCD-treated animals swam less distance than Vehicle-treated animals. That is, ovarian 
follicular depletion in older animals bestowed a beneficial effect on learning and memory 
retention for a novel spatial reference memory task. Effects were similar when a covariate 
was included to control for pre-existing differences in performance during WRAM 
training. This result provides evidence that the negative memory effects often noted in the 
post-menopausal state do not extend to all learning and memory domains. In addition, it 
is noteworthy that the VCD-treated animals have been in a post-menopausal state for 
several months at this time point and likely have a more stable circulating hormone 
profile, including a significant decrease in progesterone that could benefit spatial 
reference memory performance (discussed below). Of note, within the VCD-treated 
cohort, an Age effect revealed that follicle-deplete middle-aged animals had a higher 
swim distance to the platform, interpreted as poorer performance, compared to follicle-
deplete younger animals. Since a concordant age-related difference was not seen in 
Vehicle-treated animals, this suggests that again, VCD induced follicular depletion 
exacerbated age-related effects. This Age effect became marginal with the addition of the 
covariate, but the pattern was the same. It is noteworthy that the probe trial indicated that 
all groups localized to the previously platformed quadrant, demonstrating that the animals 
were effectively utilizing a spatial strategy to solve the MM, regardless of ovarian status 
or age. 
The Visible Platform task verified that, after six months of testing, the animals 
included in these analyses were still able to see as well as perform the motoric 
components of the task, even with advanced age.  
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Endocrine and Ovarian Markers 
A hallmark of the human transition into a post-menopausal state is a significant 
decrease in circulating ovarian hormone levels. During the transitional phase, serum 
hormone levels may be erratic as a result of irregular ovulation patterns and disrupted 
hypothalamic-pituitary-ovarian communication. Evaluations of the four primary ovarian 
hormones, 17β-Estradiol, Estrone, Progesterone, and Androstenedione at the subset 
sacrifice time point (that is, at the early menopause transition time point) indicated that 
younger VCD-treated animals had decreased Androstenedione as well as decreased 
Progesterone compared to Middle-Aged VCD-treated animals, possibly indicating that 
the younger animals experienced a more rapid decline in ovarian follicle reserve; yet, 
estrogen levels were not different at this time point. In the post-menopausal time point, 
both Young and Middle-Aged VCD-treated cohorts had less Progesterone than Vehicle-
treated counterparts. A key characteristic of menopause is the decline in circulating 
Progesterone levels resulting from anovulation and, consequently, no formation of the 
corpora lutea to secrete Progesterone. Exogenous Progesterone has been implicated in 
impaired spatial memory performance in middle-aged Ovx rats (Bimonte-Nelson et al., 
2004, 2006); perhaps the elevated Progesterone levels in the Vehicle-treated animals 
observed at the end time point can explain the older VCD-treated animals’ advantage 
over their Vehicle-treated counterparts in the MM task discussed above.  
Additionally, both Young and Middle-Aged VCD cohorts exhibited marginally 
lower Estrone levels compared to Vehicle-treated counterparts. This decrease in Estrone 
may be particularly meaningful for the Middle-Aged cohort, as VCD-treated subjects had 
marginally more errors on trial four of the last WRAM retest, and correlations of serum 
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hormone levels with MM performance suggest that higher Estrone levels were related to 
less swim distance in the MM for the Middle-Aged VCD-treated animals. Further, 17β-
Estradiol positively correlated with target quadrant localization in the probe trial of the 
MM when all animals were included in the analysis. When correlations were run for each 
group independently, 17β-Estradiol positively correlated with target quadrant localization 
for both Middle-Aged Vehicle- and Middle-Aged VCD- treated groups. Additionally, 
higher Estrone levels positively correlated with target quadrant localization for Middle-
Aged VCD-treated animals, suggesting that higher Estrone levels were associated with 
better spatial localization for this group.  
Recent clinical literature suggests that ovarian follicle counts may be a reliable 
biomarker to determine reproductive status, over and above other measurements such as 
serum hormone levels. Indeed, serum hormone levels may not be a reliable measurement 
across the transition to menopause because they are in a constant flux. More stable 
markers, such as antimüllerian hormone levels to estimate the nongrowing follicle 
population, as well as antral follicle count, may be key to determining individual 
trajectories into the post-menopausal state. Ovarian follicle counts quantified here were 
an excellent guide to determine the rats’ progression into reproductive senescence. 
During the subset sacrifice within the early menopause transition, a snapshot of the 
progression into follicle depletion was obtained. For primordial (non-growing) follicles, 
the VCD-treated animals had fewer follicles than Vehicle-treated animals in both age 
cohorts; for primary follicle counts, Young VCD-treated animals had fewer cells than 
age-matched counterparts, and Middle-Aged VCD-treated animals had marginally fewer. 
These results verify that the VCD treatment effectively targeted the resting ovarian 
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follicle pool by initiating accelerated depletion of the pool. Interestingly, Young Vehicle-
treated animals had marginally more primordial follicles than Middle-Aged Vehicle-
treated counterparts, indicating that rats naturally experience some follicle depletion 
during aging; this loss of ovarian follicles is clearly not as extreme as is the case with 
VCD-induced ovarian changes, as evidenced by the fact that both VCD-treated age 
groups had significant follicular depletion of non-growing follicles at the time of the 
subset analysis. Antral follicle count, which is most often used in the clinical setting as a 
reliable marker of reproductive capacity, differed within the Young cohort, such that 
VCD-treated animals had fewer antral (pre-ovulatory) follicles compared to age-matched 
Vehicle-treated counterparts. The Middle-Aged cohort did not exhibit the same effect – 
VCD and Vehicle treated animals did not differ in antral follicle count at this subset snap 
shot. At the subset time point, within the Young and within the Middle-Aged cohorts, 
corpora lutea did not differ depending on treatment; this null effect was also seen within 
the VCD cohort and within the Vehicle cohort. Evidence of corpora lutea in the ovary at 
this early menopause transition time point indicates that even animals undergoing 
accelerated follicular depletion still experience intermittent ovulatory cycles – this is akin 
to women’s irregular ovulatory cycles in the early menopause transition (O’Connor et al., 
2009).  
At the end of the study, within the Young cohort and within the Middle-Aged 
cohort, there were main effects of VCD treatment for all ovarian follicle types, as well as 
for corpora lutea, wherein animals that had undergone VCD-induced follicular depletion 
had fewer ovarian follicles and corpora lutea than Vehicle-treated animals. Indeed, VCD-
treated animals had no quantifiable antral follicles at analysis, indicating the halting of 
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normal ovulatory cycles and follicle maturation in these animals after the transition to a 
post-menopausal state. Although older VCD-treated animals had marginally more 
corpora lutea than younger VCD-treated counterparts, there was no difference in 
circulating Progesterone levels between these groups at this time point, indicating that, 
despite VCD-treated animals experiencing intermittent ovulation, the few corpora lutea 
produced are not sufficient to generate a significant impact on resulting spatial memory 
performance. Of interest, older Vehicle-treated animals had fewer primordial, primary, 
and secondary follicles than their younger counterparts, corroborating the idea that as 
aging ensues rodents experience a natural decline in the ovarian follicle pool over time 
(for review, see Finch 2014), though not to the same extent as the profile of a VCD-
induced deplete rat, or a menopausal woman, would look like. Within the VCD cohort, 
ovarian follicle counts did not differ between the ages, suggesting that overall, follicular 
depletion was successfully induced in both age groups.  
Broad Interpretations, Translational Implications, and Conclusions 
To our knowledge, this is the first study to perform a longitudinal, repeated 
measures evaluation of ovary intact female rats comparing subjects with or without VCD-
induced follicular depletion to model human menopause. Several key findings are 
presented here: (1) undergoing the transition to menopause at a younger age is 
detrimental to memory performance compared to age-matched, reproductively competent 
individuals, at least during the early stages of the transition to reproductive senescence; 
(2) follicular depletion amplifies age-related changes in the mid- and late- transitional 
menopause phases; (3) in a post-menopausal state, ovarian follicular depletion in older 
subjects may confer an enhanced capacity to solve a novel spatial memory task, and (4) 
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higher circulating estrogen levels benefit spatial reference memory in these older, 
follicle-deplete animals. While our laboratory has previously shown that surgically 
menopausal animals administered exogenous Estrone treatment or Androstenedione 
treatment impaired spatial memory (Camp et al., 2012; Engler-Chiurazzi et al., 2012), 
and that Androstenedione likely results in memory impairments in middle-aged Ovx rats 
due to its aromatization to Estrone (Mennenga et al., 2015a), we also showed that in the 
presence of other estrogenic steroids, a higher Estrone to 17β-Estradiol ratio was 
correlated with better WRAM performance (Engler-Chiurazzi et al., 2011). In the present 
study, 17β-Estradiol levels were not different within the Young and within the Middle-
Aged cohorts, regardless of Vehicle or VCD treatment. Yet, higher 17β-Estradiol levels 
were correlated with better target quadrant localization for Middle-Aged Vehicle- and 
Middle-Aged VCD- treated animals. In addition, for Middle-Aged VCD-treated animals, 
higher Estrone levels were correlated with better performance during test trials as well as 
better target quadrant localization during the probe trial in the MM. These results support 
the tenet that the endogenous ovarian hormone milieu has variable effects on memory 
depending on age, and potentially depending on status of follicular depletion. That 
hormones and aging might interact for memory is not surprising given that ovarian 
hormones and aging are each known to impact brain regions and systems intimately 
linked to memory. In fact, ovarian hormones and aging impact many of the same brain 
regions, including the hippocampus and basal forebrain, and many of the same 
neurotransmitter systems, including the cholinergic system (for review, see Acosta et al., 
2013; Mennenga et al., 2013).  
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Many factors, including the appropriate timing, duration, hormone formulation, 
dose, and route of administration are involved in developing hormone therapy regimens 
that will result in the attenuation of physiological menopause symptoms as well as 
potential beneficial effects for cognition. To add complexity to this puzzle, what is 
optimal for one woman may not have the same effect for another woman (for review, see 
Koebele & Bimonte-Nelson, 2015). Our findings provide further insight into the window 
of opportunity for hormone therapy by revealing that the age at the onset of the 
menopause transition and the corresponding endogenous ovarian hormone environment 
matters for memory outcomes. The finding that experiencing follicular depletion at a 
younger age results in spatial memory deficits compared to age-matched controls not yet 
undergoing the transition to a reproductively senescent state corroborates clinical findings 
that younger women who experienced oophorectomy prior to the onset of natural 
menopause had poorer short-term verbal scores than those who experienced 
oopherectomy later in life (Nappi et al., 1999). Taken together, these findings indicate 
that age at menopause onset is an important parameter that impacts cognitive outcomes. 
Whether the age at menopause influences efficacy of hormone therapy is an important 
consideration as a next research step. Elucidating the impact of age, ovarian status, and 
hormone changes on spatial memory across the transition to a reproductively senescent 
state is key in developing personalized hormone therapy regimens that can be translated 
to the clinic for women experiencing the menopause transition. Understanding the 
dynamic nature of the menopausal hormone milieu and potential interactions with 
subsequent hormone therapy is key to deciphering parameters for optimal healthy brain 
aging profiles in women who retain their ovaries throughout the lifespan. 
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